A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)
Completed
- Conditions
- Atrial Fibrillation
- Registration Number
- NCT05044533
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this observational study is to identify participants with both minor and major bleeds as a result of anticoagulant treatment for AF and evaluating their QoL through both primary and secondary care settings.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Adult patients (>= 18 years old)
- Patients who can understand all study information and literature to provide fully informed consent
- Atrial fibrillation (AF) as the primary diagnosis
- Having a major or minor bleed up to a maximum of 30 days prior to point of enrolment
- Receiving oral anticoagulation therapy for AF
Exclusion Criteria
- Pregnant women
- Patients with active cancer
- Patients unable to consent for themselves
- Patient on concomitant antiplatelet therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Distribution of characteristics of AF participants: Quality of life (QoL) data Up to 90 days Distribution of characteristics of AF participants: Impact of the anticoagulation treatment Up to 90 days
- Secondary Outcome Measures
Name Time Method Distribution of outcomes of AF participants: Timing of bleeding occurrence Up to 90 days Distribution of outcomes of AF participants: Nature of the bleed Up to 90 days Distribution of outcomes of AF participants: Documented cause of bleed Up to 90 days Distribution of outcomes of AF participants: Current Bleeding treatment Up to 90 days Distribution of outcomes of AF participants: Location of bleed Up to 90 days
Trial Locations
- Locations (1)
Local Institution - 0001
🇬🇧Swansea, United Kingdom